Despite observing problems with the way cutoff points and false-positive and negative-rates were established in a pivotal study of Baebies Inc.'s Seeker System, a US FDA advisory panel decided that the medical need for the unique screening system outweighed its weaknesses.
Members of the Clinical Chemistry and Clinical Toxicology Devices panel discussed at length the precision of Baebies' screen in finding...





